KCNH2 and cholangiocarcinoma: ADMET predictions indicate tiliacorinine is a CYP3A4 substrate with minimal CYP inhibition, low CNS penetration (appropriate for CCA treatment), and safety flags including AMES positivity and potential hERG inhibition-necessitating further experimental validation.